Rationale: Tetrahydrobiopterin (BH4) is an essential cofactor of nitric oxide synthases (NOS). Oral BH4 supplementation preserves cardiac function in animal models of cardiac disease; however, the mechanisms underlying these findings are not completely understood.
T etrahydrobiopterin (BH4) is an essential cofactor of all nitric oxide synthases (NOS). Although its role remains incompletely defined, BH4 is thought to facilitate electron transfer from the NOS' reductase domain, maintain the heme prosthetic group in its redox active form, stimulate NO synthesis, and promote the formation of active NOS homodimers. 1 Decreased BH4 bioavailability can lead to NOS uncoupling; a phenomenon whereby reduction of oxygen by NOS is uncoupled from L-arginine oxidation, resulting in the formation of superoxide rather than nitric oxide (NO). 2 A reduction in BH4 bioavailability has been demonstrated in a number of vascular disease states [3] [4] [5] and, more recently, also in the myocardium in the presence of left ventricular (LV) pressure overload, 6, 7 severe ischemia, 8 hyperglycemia, 9 and atrial fibrillation. 10 Under these conditions, supplementation of BH4 has been shown to prevent adverse remodeling and improve cardiac function 6 -8 ; however, whether this is due to a specific increase in myocardial BH4 and NO bioavailability or to the anti-inflammatory and antioxidant effects of BH4 11, 12 is still a matter of debate. Indeed, to what extent BH4 can be transported across the plasma membrane remains uncertain. 13 To date, investigations have largely focused on the role of BH4 on endothelial NOS3 activity, [3] [4] [5] [6] whereas the regulation of myocardial constitutive NOS1 activity by BH4 has received comparatively little attention. Reduced availability of NOS1-derived NO has been shown to affect basal and ␤-adrenergic contraction, 14, 15 impair myocardial relaxation by decreasing the rate of Ca 2ϩ reuptake in the sarcoplasmic reticulum (SR), 7,16 -18 and exacerbate adverse LV remodeling after myocardial infarction. 16, 19 Whether myocardial BH4 availability is a limiting factor for NOS1 activity and the NOS1-dependent regulation of myocardial function and Ca 2ϩ handling remains to be assessed. To address these issues, we generated a mouse overexpressing the rate-limiting enzyme in BH4 biosynthesis, GTP cyclohydrolase-1 (GCH1) under the control of the ␣-myosin heavy chain (␣-MHC) promoter, and investigated the impact of this intervention on the myocardial NO-redox balance, contractile function, and Ca 2ϩ fluxes.
Methods
All studies were conducted in accordance with the United Kingdom Home Office Animals (Scientific Procedures) Act of 1986.
Transgenic male animals expressing the human GCH1 gene, incorporating a human influenza hemagglutinin (HA) tag on the N-terminus, under the regulation of the ␣-MHC promoter, were generated and bred in the Functional Genetics Facility of the University of Oxford. A diagram of the DNA construct is shown in Online Figure I. GCH1 transgenic mice (mGCH1-Tg) and their wild-type (WT) littermates were housed in a temperature-controlled environment (20°C-22°C) with a 12-hour light-dark cycle. Myocardial biopterins, NOS, and GCH1 activity were assessed by highperformance liquid chromatography (HPLC) and superoxide production by lucigenin (5 mol/L)enhanced chemiluminescence. Left ventricular (LV) function was evaluated in Langendorff-perfused hearts, whereas cell shortening, [Ca 2ϩ ] i transients (Fura-2) and SR content (estimated by the amplitude of the caffeine-induced [Ca 2ϩ ] i transient and the integral of the Na ϩ /Ca 2ϩ exchanger, NCX), I Ca density, and intracellular Ca 2ϩ buffering capacity were measured in field-stimulated (3 Hz, 35°C, 1.4 mmol/L [Ca 2ϩ ] o ) or patch-clamped LV myocytes. The diastolic Ca 2ϩ leak through the Ryanodine receptor (RyR2) was estimated, as described by Shannon et al. 20 Details of the methods are included in the Online Supplement.
Results

GCH1 Overexpression Increases Myocardial GCH1 Activity and Biopterin Levels
Heterozygous mGCH1-Tg mice were viable and fertile and did not exhibit any difference in appearance, behavior, body weight, cardiac mass, or myocyte size when compared with their WT littermates (Table) . Human GCH1 protein was significantly increased in the myocardium of the mGCH1-Tg mouse, but was absent from other tissues, such as the liver and skeletal muscle ( Figure 1A) . These results were confirmed using an antibody raised against the HA tag of the transgenically expressed human GCH1 protein. The murine constitutive GCH1 level remained unchanged in all the examined tissues ( Figure 1A) .
The transgenically expressed human GCH1 protein formed functional enzymes, as shown by the significantly higher myocardial GCH1 activity ( Figure 1B ) and tissue concentrations of BH4 and total biopterins (including 7, 8-dihydrobiopterin, BH2, and fully oxidized biopterin, B) in mGCH1-Tg mice ( Figure  1C ). By contrast, biopterin levels in plasma, skeletal muscle, and liver were not different from WT ( Figure 1E ).
Immunostaining showed a similar intracellular localization of the native and transgenically expressed HA-tagged GCH1 enzyme in murine LV myocytes (Figure 2A) . Similarly, tetracycline-induced expression of the GCH1-HA fusion protein in 3T3 fibroblasts (GCH-Tet) at a level comparable to that of native GCH1 in sEnd.1 endothelial cells resulted in similar enzyme's activity and BH4 content ( Figure 2B ), indicating that the HA tag did not alter GCH1 activity and intracellular localization.
Whether biopterins can be transported across the sarcolemmal membrane remains uncertain. To evaluate whether increased myocardial GCH1 activity leads to an increase in biopterins content in the neighboring tissue, we compared biopterins concentration in the cardiomyocyte-enriched and nonmyocyte fractions of cells enzymatically isolated from mGCH1-Tg hearts. As shown in Figure 2C , we detected a very small increase in BH4 and total biopterins in the nonmyocyte fraction of mGCH1-Tg hearts, indicating either low-level transport of biopterins from myocytes to neighboring cells or, more likely, incomplete purification of the noncardiomyocyte fraction. By contrast, oral supplementation of BH4 (5 mg/d for 7 days 7 ) in C57BL/6 mice resulted in a significant increase in BH4 ( Figure 2D ) and the BH4:BH2ϩB ratio (0.80Ϯ0.04 versus 0.58Ϯ0.07 in mice treated with the enzymatically inactive analog of BH4 tetrahydroneopterin, H4N; nϭ6 and 5 hearts, PϽ0.05) in purified LV myocytes and in a borderline rise in NOS activity (% L-Citrulline conversion: 0.47Ϯ0.07 versus 0.30Ϯ0.05 in H4N treated mice; nϭ6 and 5 hearts, Pϭ0.065). Thus, whereas oral supplementation leads to an increase in LV myocytes BH4, the BH4 synthetized by LV myocytes is not exported to neighboring tissues.
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GCH1 Overexpression Increases Myocardial NOS1 Activity and Reduces Superoxide Production
NOS activity is thought to be dependent on both BH4 bioavailability and the ratio between BH4 and its oxidized Figure 1 . Myocardial GCH1 overexpression causes a tissue-specific increase in GCH1 activity and biopterin content. Antihuman GCH1 and HA tag antibodies showed a myocardialspecific overexpression of hGCH1 in mGCH1-Tg mice. Murine native GCH1 did not differ between genotypes (A). Both GCH activity (by HPLC, nϭ8 and 12 hearts per genotype; *** PϽ0.0001, B) and biopterin level (nϭ9 hearts per genotype; **PϽ0.001, C) were increased in mGCH1-Tg hearts, but the ratio between BH4 and its oxidized products (BH2ϩB) decreased in mGCH1-Tg hearts (*PϽ0.02, D). The BH4 and biopterin content in plasma, muscle, and liver tissue did not differ between genotypes (E). HA indicates haemagglutinin; mGCH1, myocardial guanosine triphosphate cyclohydrolase; Tg, transgenic; BH4, tetrahydrobiopterin; BH2, 7, 8-dihydrobiopterin.
Figure 2. The HA tag does not alter GCH1 localization or activity and the effect of oral BH4 supplementation on cardiomyocyte biopterin content and NOS activity. A,
Immunolocalization of native (left side, in red) and human HA-tagged GCH1 (middle, in red) in WT and mGCH1-Tg LV myocytes, respectively. The right side shows myocytes exposed to Alexa Fluor 555 conjugate only. Cells nuclei were counterstained with TO-PRO®-3 (in blue). Scale bar: 10 m. B, Tetracyclineinduced expression of human GCH-HA protein (hGCH1) in 3T3 fibroblasts (GCH-tet) at a comparable level to native GCH1 in sEnd.1 murine endothelial cells results in similar GCH1 activity and intracellular BH4 levels. C, The increase in biopterins in mGCH1-Tg mice was largely limited to the LV myocytes fraction (nϭ6 and 5 hearts, ***PϽ0001, **PϽ001, and *PϽ0.01). D, BH4 oral supplementation (5 mg/d) augmented the BH4 and total biopterins content in LV myocytes from C57BL/6 mice (versus H4N-supplemented mice, nϭ5 and 6 hearts, respectively, ***PϽ0.001 and **PϽ0.01). HA indicates haemagglutinin; BH4, tetrahydrobiopterin; NOS, nitric oxide synthases; WT, wild-type; mGCH1, myocardial guanosine triphosphate cyclohydrolase; Tg, transgenic; LV, left ventricle.
products. 21, 22 In mGCH1-Tg mice, myocardial BH4 was increased but so were the levels of its oxidized products ( Figure 1C ), resulting in a reduction in the BH4:BH2ϩB ratio when compared with WT mice ( Figure 1D ). Because the K m of BH4 and of its oxidized product BH2 for NOS is similar (but only BH4 can serve as NOS cofactor), excess BH2 may displace BH4 from NOS, leading to NOS uncoupling and increased superoxide production. 21, 22 To test this possibility, we evaluated myocardial NOS activity and superoxide production in mGCH1-Tg mice and their WT littermates. As shown in Figure 3A , myocardial transgenic expression of GCH1 was associated with a significant increase in total NOS activity in LV homogenates. The SMTC-inhibitable (ie, NOS1-attributable) component of NOS activity in mGCH1-Tg hearts accounted for approximately 70% of the total, and was again significantly higher in mGCH1-Tg hearts than in WT hearts, whereas NOS3 activity did not change appreciably. Immunoblotting showed that myocardial constitutive and inducible NOSs did not differ between genotypes ( Figure 3B ).
Superoxide production was significantly reduced in LV homogenates from mGCH1-Tg mice (in RLU/mg protein/s, 64.3Ϯ6.7 in WT versus 47.6Ϯ4.6 in mGCH1-Tg mice, PϽ0.05, nϭ14 hearts per group); incubation with L-NAME did not decrease superoxide release in LV homogenates from mGCH1-Tg mice (versus D-NAME) nor affect the difference in superoxide production between genotypes ( Figure 3C ), indicating that NOS activity is not uncoupled in the mGCH1-Tg myocardium (despite the decrease in the BH4:BH2ϩB ratio), and the reduction in superoxide release in mGCH1-Tg mice is not secondary to an NO-mediated inhibition of oxidases activity or the direct scavenging of superoxide by increased NO production.
Effect of Myocardial GCH1 Overexpression and Increased NOS1 Activity on LV Contraction: Role of I Ca and SR Ca 2؉ Release
NOS1 gene deletion has been reported to slow the rate of myocardial relaxation and SR Ca 2ϩ uptake 7,16 -18 and to have variable effects on I Ca , myocardial inotropy 14, 15, 17 and the diastolic leak of Ca 2ϩ through the RyR2. 23, 24 In mGCH1-Tg mice, increased NOS1 activity did not affect LV systolic function (Online Figure II) or cardiomyocyte basal and ␤-adrenergic stimulated contraction ( Figure 4A and Online Figure III) . Similarly, diastolic Ca 2ϩ (Fura 2 ratio: 1.31Ϯ0.04 in WT versus 1.27Ϯ0.03 in mGCH1-Tg, nϭ36 and 38 cells, 4 hearts per genotype; Pϭ0.3) and the amplitude of the [Ca 2ϩ ] i transient ( Figure 4B ) did not differ between genotypes, whereas the SR Ca 2ϩ content tended to be lower in mGCH1-Tg ( Figure 4C ). By contrast, I Ca density was significantly reduced in mGCH1-Tg myocytes at voltages from 0 to ϩ20 mV ( Figure 4D ). At 0 mV, I Ca density was Ϫ6.8Ϯ0.5 pA/pF in mGCH1-Tg and Ϫ8.4Ϯ0.4 in WT (PϽ0.05, nϭ26 and 21 cells from 5 and 4 hearts per genotype, respectively). Steady state inactivation curves showed that the voltage at which I Ca was half-maximally inactivated was Ϫ29.3Ϯ0.1 mV in WT and Ϫ34.1Ϯ0.2 mV in mGCH1-Tg myocytes (PϽ0.05), whereas activation curves did not differ between groups (Online Figure IB) . Both the fast and slow time constants of decay of I Ca were significantly shorter in mGCH1-Tg myocytes ( f in milliseconds: 25.8Ϯ1.0 versus 30.1Ϯ1.1 in WT, PϽ0.05 and s in milliseconds: 99.9Ϯ7.2 versus 136.7Ϯ5.9 in WT, PϽ0.01). NOS1 inhibition with . NOS activity is increased and superoxide production is reduced in mGCH1-Tg hearts. A, Total NOS activity (L-NAME-inhibitable) was significantly increased in the myocardium of mGCH1-Tg mice (nϭ8 and 7 hearts per genotype, ***PϽ0.0001) and accounted for by an increase in the SMTC-inhibitable, NOS1-dependent fraction (**PϽ0.0001). By contrast, NOS3 activity (estimated by subtracting the SMTC-inhibitable fraction from the total NOS activity) was unchanged. B, Myocardial NOS isoforms did not differ between genotypes (nϭ6 -7 hearts per genotype). C, Superoxide production was significantly lower in mGCH1-Tg hearts. Incubation with L-NAME (1 mmol/L versus D-NAME) did not affect myocardial superoxide production in either group (results are shown as the Tiron-inhibitable fraction in RLUs/mg protein/s; nϭ6 -7 hearts per genotype; *PϽ0.05 between groups). NOS indicates nitric oxide synthases; mGCH1, myocardial guanosine triphosphate cyclohydrolase; Tg, transgenic; SMTC, S-methyl-L-thiocitrulline acetate salt.
SMTC significantly increased I Ca in mGCH1-Tg mice (Figure 4D) but not in WT mice (data not shown), and abolished the differences in I Ca between genotypes. Despite a reduction in peak I Ca and a trend toward a lower SR load in mGCH1-Tg mice, the fractional release of Ca 2ϩ from the SR was increased in mGCH1-Tg myocytes (83.4Ϯ2.2% versus 75.9Ϯ2.4% in WT myocytes; nϭ36 and 38 cells, 4 hearts per genotype, PϽ0.05), suggesting that the sensitivity of RyR2 Ca 2ϩ release channel to activation by local Ca 2ϩ is increased in mGCH1-Tg mice. 25 The critical role of the increased fractional release of Ca 2ϩ from the SR in preserving normal myocardial contraction in the mGCH1-Tg mouse was confirmed by measuring cell shortening in the presence of thapsigargin. As shown in Figure 5A , disabling the SR resulted in a significantly smaller contraction in mGCH1-Tg cardiomyocytes, in keeping with the reduced Ca 2ϩ influx via the L-type Ca 2ϩ channels in these mice (peak I Ca density in thapsigargin-treated cells in pA/pF: Ϫ6.9Ϯ0.9 in WT, nϭ7 cells from 3 hearts versus Ϫ4.3Ϯ0.4 in GCH1-Tg, nϭ10 cells from 4 hearts, PϽ0.05).
Next, we evaluated whether an increase in RyR2 S-nitrosylation and diastolic Ca 2ϩ leak might have contributed to the trend toward a reduction in SR Ca 2ϩ load in mGCH1-Tg mice. As shown in Figure 5B , RyR2 S-nitrosylation was increased in mGCH1-Tg mice, and this was associated with a larger diastolic Ca 2ϩ leak ( Figure 5C ); however, inhibition of the RyR2 leak with tetracaine did not change SR Ca 2ϩ load appreciably in either group (Fura2 ratio: 0.65Ϯ0.07 versus 0.68Ϯ0.08 in WT and 0.50Ϯ0.11 versus 0.43Ϯ0.09 in mGCH1-Tg myocytes, Pϭns, nϭ5 and 6 cells, respectively, from 3 hearts per genotype).
Mechanisms Underlying the Faster Rate of Myocardial Relaxation and [Ca 2؉ ] i Decay in mGCH1-Tg Mice
As shown in Figure 5D , the exponential decay of LV pressure during isovolumic relaxation (tau) was significantly faster in Langendorff-perfused mGCH1-Tg hearts, whereas the LV end-diastolic pressure-volume relationship did not differ between genotypes (Online Figure II ), suggesting that LV compliance and structural properties were unaffected in mGCH1-Tg hearts. In agreement with these data, cell size was the same (Table) , but the rate of relengthening (ϪdL/dt) was faster in field-stimulated LV myocytes from mGCH1-Tg mice (Figures 4A and 5E ) and so was the decay of the [Ca 2ϩ ] i transient ( Figures 4B and 5F) .
To evaluate the mechanisms responsible for these findings, we first measured the amplitude of the NCX current (which by extruding Ca 2ϩ across the sarcolemmal membrane may affect the speed of relaxation and [Ca 2ϩ ] i decay). As shown in Online Figure IVA , the NCX current did not differ between genotypes nor did the rate of decay of the caffeine-induced [Ca 2ϩ ] i transient (which predominantly reflects the rate of Ca 2ϩ extrusion from the cell via the NCX, Online Figure  IVB) . The calcium flux through NCX, calculated as the integral of the current, did not differ significantly between genotypes (pC/pF: 0.70Ϯ0.08 in mGCH1-Tg versus 0.97Ϯ0.12 in WT; nϭ12 and 8 cells, respectively, from 3-4 hearts per genotype, Pϭ0.11). As GCH1 is a Ca 2ϩ -binding enzyme, 26 we also evaluated whether its overexpression affected the myocytes' Ca 2ϩbuffering properties (Online Figure IVC) . The maximum intrinsic Ca 2ϩ buffering capacity (B max ) and the dissociation constant (K d ) did not differ between genotypes (B max in mol/L: 112.5Ϯ7.0 in WT versus 124.4Ϯ8.0 in mGCH1-Tg; nϭ10 and 7 cells, respectively, from 3-4 hearts per genotype; Pϭ0.29; K d in mol: 0.84Ϯ0.06 in WT versus 0.74Ϯ0.07 in mGCH1-Tg, Pϭ0. 30 ), suggesting that the [Ca 2ϩ ] i -buffering capacity was unaffected by myocardial GCH1 overexpression.
The absolute level of SERCA2A protein and Ser 16 phosphorylated PLB did not differ between genotypes, but total PLB was significantly reduced in mGCH1-Tg ( Figure 6A) ; consequently, both the PLB Ser 16 phosphorylated fraction and the SERCA2A: PLB ratio were significantly increased in mGCH1-Tg mice. By contrast, the PLB Thr 17 phosphorylated fraction did not differ between genotypes.
Because SERCA2A activity is inhibited by unphosphorylated PLB, both the reduction in total PLB and the relative increase in PLB Ser 16 phosphorylation may contribute to the faster rate of [Ca 2ϩ ] i decay and relaxation in mGCH1-Tg myocytes. However, by abolishing the difference in PLB Ser 16 phosphorylation between genotypes (in the absence of changes in total PLB), NOS1 inhibition with SMTC also abolished the differences in the rate of relaxation and [Ca 2ϩ ] i decay between mGCH1-Tg and WT mice ( Figure 7A and  7B) . Similarly, ␤-adrenergic stimulation (isoproterenol, 10 nmol/L) or PKA inhibition (PKI, 3 mol/L) abolished both the difference in PLB Ser 16 phosphorylation and the rate of [Ca 2ϩ ] i decay between genotypes (Online Figures III and  VIB) , whereas inhibition of type 1 or type 2A protein phosphatases by okadaic acid (2 mol/L) did not affect PLB phosphorylation in either group (Online Figure VA) . PKI did not affect the amplitude of the [Ca 2ϩ ] i transient in either group (data not shown).
The role of SR Ca 2ϩ reuptake in determining the faster rate of relaxation in mGCH1-Tg mice was further confirmed by showing that, after disabling the SR with thapsigargin, myocyte relaxation tended to be slower in mGCH1-Tg mice (ϪdL/dt in m/s: 9.3Ϯ1.5 versus 14.1Ϯ2.1 in WT; nϭ7 and 12 cells from 3 hearts per genotype, Pϭ0.073).
Taken together, these findings indicate that a NOS1dependent increase in PKA-mediated Ser 16 PLB phosphorylation is the main mechanism underlying the faster relaxation and [Ca 2ϩ ] i decay dynamics in LV myocytes from mGCH1-Tg mice.
Decreased Superoxide Production Does Not Affect the Myocardial Phenotype of mGCH1-Tg Mice
In the myocardium of NOS1 knockout mice, an increase in XOR-dependent superoxide production has been reported to account for a decreased cell shortening at frequencies Ͼ1 Hz. 27, 28 To evaluate whether a reduction in myocardial superoxide production might have contributed to the phenotype of the mGCH1-Tg mice, LV myocytes were incubated with the XOR inhibitor, oxypurinol (100 mol/L). As shown in Online Figure VB , oxypurinol decreased myocardial superoxide production in WT mice and abolished the differences between groups, but it did not affect LV myocyte relaxation or contraction in either genotype ( Figure 7C ). 
Discussion
The present study demonstrates that ␣-MHC-driven GCH1 overexpression leads to a myocardial-specific increase in biopterins content and improves basal myocardial relaxation through a NOS1-dependent increase in PKA-mediated Ser 16 PLB phosphorylation. This conclusion is supported and complemented by a number of novel findings. First, the significant increase in myocardial BH4 and biopterins concentration in mGCH1-Tg mice did not affect their plasma level or the nonmyocyte component of the LV myocardium. By contrast, BH4 and total biopterins content in LV myocytes was increased following oral BH4 supplementation in C57BL/6 mice, indicating that biopterins transport across the sarcolemmal membrane may be unilateral. Second, despite a large increase in myocardial BH4, the ratio between BH4 and its oxidized products (BH2 and B) was lower in mGCH1-Tg mice, indicating that a large proportion of the myocardial biopterin pool was oxidized. Even so, myocardial NOS1 activity was increased in mGCH1-Tg mice, and superoxide release was lower and unaffected by NOS inhibition, indicating that NOS activity remained coupled under these conditions. Third, both the speed of relaxation and the rate of decay of the [Ca 2ϩ ] i transient were faster in mGCH1-Tg mice. These findings were associated with an increase in the PLB Ser 16 phosphorylated fraction and in the SERCA2A:PLB ratio. NOS1 or PKA inhibition reduced Ser 16 PLB phosphorylation to a similar level in both genotypes and abolished the difference in the rate of decay of the [Ca 2ϩ ] i transient. Similarly, overriding the differences in PKA-mediated Ser 16 PLB phosphorylation between mGCH1-Tg and WT mice with isoproterenol abolished the differences in the rate of relaxation and Ca 2ϩ decay. Fourth, an increase in fractional release of Ca 2ϩ from the SR was responsible for preserving LV inotropy and the amplitude of the [Ca 2ϩ ] i transient in mGCH1-Tg mice, despite a significant reduction in I Ca density. The diastolic Ca 2ϩ leak through the RyR2 was significantly increased in mGCH1-Tg cardiomyocytes; however, under our experimental conditions, this did not have a significant impact on SR Ca 2ϩ load. After disabling the SR with thapsigargin, cell shortening was decreased in mGCH1-Tg mice, and the rate of relaxation did not differ between genotypes. Finally, XOR inhibition with oxypurinol abolished the differences in superoxide production between genotypes but did not affect cell shortening or the rate of relaxation in either group.
Together, these findings identify cardiac myocyte GCH1 activity and BH4 content as important regulators of EC coupling and LV relaxation, through their limiting effect on NOS1 activity and the PKA-mediated Ser 16 PLB phosphorylation, and suggest that increasing myocardial GCH1 activity and BH4 content may be a promising strategy for the treatment of LV diastolic dysfunction.
Transsarcolemmal Biopterins Transport and Myocardial Availability
Evidence indicates that exogenous BH4 is first oxidized to BH2 in the plasma and then transported into the cell, where it can be reduced back to BH4 by the dihydrofolate reductase. 29 In agreement with these findings, oral BH4 supplementation resulted in an increase in BH4 and biopterins content in isolated LV myocytes from C57BL/6 mice. By contrast, biopterins synthesized in LV myocytes from mGCH1-Tg mice remained confined within this cell type, suggesting that their transport across the cell membrane may be unidirectional.
In endothelial cells, NOS3 function and coupled state depend on the ratio between BH4 and its oxidized products 21, 22 ; failure to observe an increase in endothelial BH4:BH2ϩB ratio following oral BH4 supplementation in patients undergoing CABG surgery was associated with no improvement in endothelial NO bioavailability and vascular function, casting serious doubt on the potential of this therapeutic approach in vascular disease. 30 However, we found that the reduction in the BH4:BH2ϩB ratio was not associated with NOS dysfunction in the myocardium of mGCH1-Tg mice, in agreement with our recent data in the fibrillating atrial myocardium, where a reduction in the BH4:BH2ϩB ratio was not sufficient to cause NOS uncoupling, in the absence of a significant reduction in tissue BH4 concentration. 10 Indeed, myocardial NOS activity was significantly increased in mGCH1-Tg mice, implying that constitutive myocardial GCH1 activity and BH4 levels might be limiting NO synthesis, even in the absence of disease. Interestingly, only NOS1 activity was increased in mGCH1-Tg mice, suggesting that myocardial constitutive NOS isoforms may have different exposure or sensitivity to oxidized biopterins. Taken together, our findings indicate that an increase in myocardial NOS1 activity can be achieved in the absence of an increase in BH4 over and above the accompanying changes in oxidized biopterins.
BH4-Mediated Regulation of Myocardial Ca 2؉ Fluxes: Role of NOS1
We and others have previously reported that disrupting NOS1 function results in impaired myocardial relaxation and SR Ca 2ϩ reuptake through a reduction in PKA-dependent PLB phosphorylation. 16 -18 Here we show that increased NOS1 activity in the mGCH1-Tg myocardium leads to an increase in PLB Ser 16 phosphorylation and a faster rate of relaxation and [Ca 2ϩ ] i decay, all of which are abrogated by NOS1 or PKA inhibition or by disabling the SR with thapsigargin. By contrast, the increase in NOS1 activity in the myocardium of mGCH1-Tg mice was not associated with significant changes in cell shortening, LV systolic function, or Ca 2ϩ transient amplitude, despite a reduction in I Ca . Indeed, the increased rate of SR Ca 2ϩ reuptake in mGCH1-Tg mice was associated with a marginally reduced SR Ca 2ϩ content, suggesting that other changes in myocardial Ca 2ϩ fluxes may be at play. Indeed, the diastolic leak of Ca 2ϩ from the RyR2 was increased in mGCH1-Tg mice; however, we did not detect a significant difference in the SR Ca 2ϩ load after inhibition of the RyR2 leak with tetracaine in either genotype. An additional explanation can be found by examining I Ca . Peak I Ca was reduced, and both the fast and slow time constants of decay of the steady state current were significantly shorter in mGCH1-Tg mice. As the inward current during slow decay of I Ca is thought to contribute to SR Ca 2ϩ loading, 31 its reduction may counteract the effect of increased SERCA2A activ- ity on SR Ca 2ϩ load of mGCH1-Tg myocytes. Interestingly, despite a significant reduction in peak I Ca , SR fractional release was increased in mGCH1-Tg myocytes; taken together with the larger diastolic Ca 2ϩ leak, these findings suggest that the sensitivity of the RyR2 to activation by local Ca 2ϩ is increased in mGCH1-Tg mice. As indicated by the data obtained in the presence of thapsigargin, the increase in SR fractional release is crucial for preserving normal contraction in mGCH1-Tg mice.
Increasing myocardial BH4 may directly scavenge reactive oxygen species and increase NO availability. We found that myocardial superoxide production was significantly lower in mGCH1-Tg mice; oxypurinol abolished the differences in superoxide release between mGCH1-Tg and WT mice but did not affect cell shortening or relaxation in either group, indicating that reduced superoxide availability does not contribute to the myocardial phenotype of the mGCH1-Tg mouse under these conditions.
Implications for the Treatment of LV Diastolic Dysfunction
The fact that increased BH4 availability has such a profound effect on myocardial relaxation, regardless of the abundance of its oxidized products, suggests that increasing GCH1 activity may be a promising therapeutic strategy in patients with LV diastolic dysfunction. At the transcriptional level, GCH1 is upregulated by proinflammatory cytokines, 32 cAMP levels, 33 and HMG-CoA reductase inhibition by statins. 34 Regulation of GCH1 activity by phosphorylation has also been reported. 35, 36 Recent evidence suggests that resveratrol activates GCH1 in murine hearts, resulting in increased BH4 levels 37 and improves LV relaxation in type 2 diabetes. 38 Importantly, our findings suggest that strategies aimed at increasing myocardial BH4 availability may hold promise in the treatment of diastolic heart failure in the presence or absence of NOS uncoupling, suggesting that this therapeutic approach may have wider-than-expected applicability.
